Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
6
×
san diego top stories
san francisco blog main
san francisco top stories
clinical trials
fda
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
akcea therapeutics
alnylam pharmaceuticals
biotech
boston
cancer
drugs
hereditary transthyretin amyloidosis
inotersen
onpattro
patisiran
pfizer
tafamidis
What
drug
6
×
medicine
6
×
fda
approved
cancer
alnylam
disease
new
rnai
afternoon
alnylam’s
alzheimer's
approves
bad
brain
case
cells
data
deeper
dna
doses
eisai
ema
employ
europe
failed
fatty
fight
fingerprint
flags
follows
fortune
gene
genetic
gets
goes
going
harmful
help
higher
Language
unset
Current search:
medicine
×
drug
×
" san diego blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug